igm biosciences, inc., a biotechnology company, engages in the research and development of immunoglobulin m (igm) antibodies for the treatment of cancer. the company's lead product candidate is igm-2323, a bispecific igm antibody that is in phase 1 clinical trials to treat patients with b cell nhl and other b cell malignancies. it is also developing igm-8444, an igm antibody targeting death receptor 5 proteins; and igm-7354, is a bispecific igm antibody delivering interleukin-15 cytokines to pd-l1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. igm biosciences, inc. has a collaboration with atreca inc. and beigene ltd. to discover, develop, and manufacture novel igm and iga antibodies targeting sars-cov-2 for the potential treatment of covid-19; and strategic research collaboration and license agreement with abcellera to discover and develop igm antibodies. the company was formerly known as palingen, inc. and changed its name to igm biosci
Company profile
Ticker
IGMS
Exchange
Website
CEO
Fred M. Schwarzer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Palingen, Inc.
SEC CIK
Corporate docs
Subsidiaries
IGM Infectious Diseases, Inc. • IGM Autoimmunity and Inflammation, Inc. ...
IRS number
770349194
IGMS stock data
Latest filings (excl ownership)
8-K
IGM Biosciences Announces Refocusing of Sanofi Collaboration
17 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
S-8
Registration of securities for employees
7 Mar 24
8-K
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
8 Dec 23
EFFECT
Notice of effectiveness
28 Nov 23
CORRESP
Correspondence with SEC
15 Nov 23
UPLOAD
Letter from SEC
14 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 175.41 mm | 175.41 mm | 175.41 mm | 175.41 mm | 175.41 mm | 175.41 mm |
Cash burn (monthly) | (no burn) | 224.67 k | 22.25 mm | 21.22 mm | 13.37 mm | 15.17 mm |
Cash used (since last report) | n/a | 1.54 mm | 152.33 mm | 145.24 mm | 91.55 mm | 103.87 mm |
Cash remaining | n/a | 173.87 mm | 23.08 mm | 30.17 mm | 83.86 mm | 71.55 mm |
Runway (months of cash) | n/a | 773.9 | 1.0 | 1.4 | 6.3 | 4.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 81 |
Opened positions | 14 |
Closed positions | 15 |
Increased positions | 27 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 161.47 bn |
Total shares | 34.04 mm |
Total puts | 1.10 k |
Total calls | 11.90 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Haldor Topsoe Holding A/S | 10.40 mm | $93.81 mm |
T. Rowe Price | 3.24 mm | $27.08 bn |
Baker Bros. Advisors | 3.16 mm | $26.37 bn |
Redmile | 2.97 mm | $24.81 bn |
Artal | 2.52 mm | $21.06 mm |
FMR | 2.14 mm | $17.84 bn |
Artal International S.C.A. | 1.33 mm | $93.44 mm |
Ra Capital Management | 937.50 k | $7.83 bn |
Vanguard | 900.01 k | $7.52 bn |
BLK Blackrock | 870.92 k | $7.27 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Mar 24 | Baker Bros. Advisors | Common Stock | Grant | Acquire A | Yes | No | 0 | 1,994 | 0.00 | 3,755,474 |
29 Mar 24 | Baker Bros. Advisors | Common Stock | Grant | Acquire A | Yes | No | 0 | 1,994 | 0.00 | 349,160 |
29 Mar 24 | Lee Michael Stewart | Common Stock | Grant | Acquire A | No | No | 0 | 1,734 | 0.00 | 5,854 |
29 Mar 24 | Topsoe Jakob Haldor | Common Stock | Grant | Acquire A | No | No | 0 | 1,734 | 0.00 | 84,854 |
29 Mar 24 | Topsoe Christina Teng | Common Stock | Grant | Acquire A | No | No | 0 | 2,687 | 0.00 | 43,606 |
News
What 5 Analyst Ratings Have To Say About IGM Biosciences
18 Apr 24
HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target
18 Apr 24
Where IGM Biosciences Stands With Analysts
8 Mar 24
RBC Capital Reiterates Outperform on IGM Biosciences, Maintains $21 Price Target
8 Mar 24
Wedbush Reiterates Outperform on IGM Biosciences, Maintains $20 Price Target
8 Mar 24